The Small Animal Imaging Shared Resource (SAISR) is a newly developed state-of-the-art imaging facility located in 5300 sq ft. of the Biomedical Research Tower (BRT), home to a majority of CCC members. The SAISR is led by Drs. Periannan Kuppusamy (Director) and Kimeriy Powell (Technical Director) and includes high-resolution small animal imaging equipment, image post-processing hardware and software, technical support personnel, and direct interface to Ohio Supercomputer (OSC) facilities. Animal housing for serial imaging studies is provided by University Laboratory Animal resources and two 100 sq ft suites are available for surgical procedures and animal preparation. The following micro imaging equipment is available within this shared resource: 1) An AVANCE 500 WB NMR Spectrometer and Imaging system (Bruker BioSpin, Germany), 2) A BioSpec 94/30 imaging system (Bruker BioSpin, Germany, 3) An Inveon? PET/CT Imaging system (Siemens, Eriangen Germany), 4) An Inveon? SPECT/PET/CT Imaging system (Siemens, Eriangen Germany), 5) An X-SPECT? SPECT/CT imaging system (Gamma Medica, Northridge, CA, USA), 6) A Vevo 2100 high frequency ultrasound system (VisualSonics, Toronto Canada), and 7) four Electron Paramagnetic Resonance (EPR) imaging systems. The primary mission of the SAISR is to provide high quality micro-imaging data to OSUCCC members at low-cost in an efficient and timely manner. Highly trained and dedicated personnel provide services to allow OSUCCC investigators to perform an imaging experiment from the design to analysis stages. SAISR staff proactively develop new imaging protocols and have implemented a web-based server system where 3D imaging data can be downloaded and interactively viewed by the investigators at their desktops. The development phase of SAISR available imaging modalities have increased from 3 to 7 and the facility has been relocated and expanded to centrally-located space near the CCC's primary vivarium. During the last 12 months the SAISR has provided service to 21 OSUCCC investigators in 5 of 6 OSUCCC Scientific Programs for 47% of the total usage. Three full-time personnel manage and operate the facility, and a comprehensive a year long seminar series has been instituted to educate cancer investigators about small animal imaging and cancer research. Furthermore, we anticipate expansion of this environment with integrated multi-modality optical and ultrasound imaging systems. Collectively, the SAISR leverages outstanding institutional support to provide cutting edge imaging instrumentation and services to support high quality cancer research.

Public Health Relevance

The Small Animal Shared Resource (SAISR) a state-of-the-art small animal imaging facility that provides OSUCCC investigators high resolution imaging equipment, highly trained personnel and outstanding support for quantitative image analysis. The SAISR provides support for high quality cancer investigations in a timely and cost-effective manner within an outstanding institutional research environment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-38
Application #
8601833
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$87,696
Indirect Cost
$30,190
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Baldassari, Federica; Zerbinati, Carlotta; Galasso, Marco et al. (2018) Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. Front Genet 9:174
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Lopez, Cecilia M; Yu, Peter Y; Zhang, Xiaoli et al. (2018) MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. PLoS One 13:e0190086
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Lampis, Andrea; Carotenuto, Pietro; Vlachogiannis, Georgios et al. (2018) MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology 154:1066-1079.e5
Le Gallo, Matthieu; Rudd, Meghan L; Urick, Mary Ellen et al. (2018) The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer 124:65-73
Jones, Jeffrey A; Mato, Anthony R; Wierda, William G et al. (2018) Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19:65-75
Madan, Esha; Parker, Taylor M; Bauer, Matthias R et al. (2018) The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53. J Biol Chem 293:4262-4276

Showing the most recent 10 out of 2602 publications